---
layout: single
title: "The Era of Tumor Superstar Targets: Spotlight on Claudin18.2"
permalink: /3DisoGalaxy/claudin18.2/
author_profile: true
---

<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Claudin18.2 in the Spotlight: Deep Dive into the Hottest Tumor Target</title>
    <style>
        /* Global Styles */
        body {
            font-family: 'Segoe UI', 'Roboto', 'Oxygen', 'Ubuntu', 'Cantarell', 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;
            background-color: #000000; /* Black background */
            color: #00FFCC; /* High-tech bright green text */
            line-height: 1.6;
            margin: 0;
            padding: 20px;
            overflow-x: hidden; /* Prevent horizontal scrollbar */
            position: relative;
        }

        /* Simulate high-tech glow effect */
        body::before, body::after {
            content: '';
            position: fixed;
            width: 100%;
            height: 100%;
            pointer-events: none;
            z-index: -1;
            opacity: 0.1;
        }

        body::before {
            background: radial-gradient(circle at top left, #00BFFF, transparent 50%),
                        radial-gradient(circle at bottom right, #FF00FF, transparent 50%);
            mix-blend-mode: screen;
        }

        body::after {
            background: linear-gradient(to right, rgba(0,255,204,0.1) 1px, transparent 1px),
                        linear-gradient(to bottom, rgba(0,255,204,0.1) 1px, transparent 1px);
            background-size: 20px 20px;
        }

        .container {
            max-width: 1000px;
            margin: 0 auto;
            background-color: rgba(10, 10, 10, 0.8); /* Slightly transparent dark background */
            padding: 40px;
            border-radius: 8px;
            box-shadow: 0 0 30px rgba(0, 255, 204, 0.2); /* Tech glow */
            position: relative;
            z-index: 1;
        }

        /* Headings */
        h1 {
            color: #00FFFF; /* Cyan title */
            text-align: center;
            font-size: 2.8em;
            margin-bottom: 40px;
            text-shadow: 0 0 15px rgba(0, 255, 255, 0.8);
            letter-spacing: 2px;
            border-bottom: 2px solid #00FFFF;
            padding-bottom: 15px;
        }

        h2 {
            color: #00BFFF; /* Blue secondary heading */
            font-size: 2em;
            margin-top: 50px;
            margin-bottom: 20px;
            border-left: 5px solid #00BFFF;
            padding-left: 15px;
            text-shadow: 0 0 10px rgba(0, 191, 255, 0.5);
        }

        h3 {
            color: #33CCFF; /* Light blue sub-heading */
            font-size: 1.6em;
            margin-top: 30px;
            margin-bottom: 15px;
            border-bottom: 1px dotted #33CCFF;
            padding-bottom: 5px;
        }

        p, li {
            color: #E0E0E0; /* Soft white text */
            margin-bottom: 10px;
        }

        ul {
            list-style-type: disc;
            margin-left: 20px;
            color: #E0E0E0;
        }

        ul li {
            margin-bottom: 5px;
        }

        /* Table styles */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 25px 0;
            font-size: 0.95em;
            color: #E0E0E0;
            background-color: rgba(30, 30, 30, 0.7);
            border: 1px solid #00BFFF;
        }

        th, td {
            padding: 12px 15px;
            text-align: left;
            border-bottom: 1px solid rgba(0, 255, 204, 0.3);
        }

        th {
            background-color: #005555;
            color: #00FFFF;
            font-weight: bold;
            text-transform: uppercase;
        }

        tr:hover {
            background-color: rgba(0, 255, 204, 0.05);
        }

        /* Image styles */
        img {
            max-width: 90%;
            height: auto;
            display: block;
            margin: 20px auto;
            border: 1px solid #00FFFF;
            box-shadow: 0 0 15px rgba(0, 255, 255, 0.5);
            border-radius: 5px;
        }

        /* Emphasized text */
        strong {
            color: #00FFFF;
        }

        em {
            color: #FFD700; /* Gold emphasis */
            font-style: normal;
        }

        a {
            color: #00FFFF;
            text-decoration: none;
        }

        a:hover {
            text-decoration: underline;
        }

        /* Section divider */
        hr {
            border: none;
            border-top: 1px dashed #00BFFF;
            margin: 50px 0;
        }

        /* "üìå" icon for section headers */
        .section-header {
            display: flex;
            align-items: center;
            font-size: 2em;
            color: #00BFFF;
            margin-top: 50px;
            margin-bottom: 20px;
            border-left: 5px solid #00BFFF;
            padding-left: 15px;
            text-shadow: 0 0 10px rgba(0, 191, 255, 0.5);
        }
        .section-header span {
            margin-right: 10px;
        }

        /* Reference section styling */
        .references {
            margin-top: 60px;
            padding-top: 20px;
            border-top: 2px solid #00FFFF;
        }

        .references h4 {
            color: #00FFFF;
            font-size: 1.8em;
            margin-bottom: 20px;
            text-shadow: 0 0 10px rgba(0, 255, 255, 0.5);
        }

        .references ul {
            list-style-type: none; /* Remove default bullet points */
            padding-left: 0;
        }

        .references li {
            margin-bottom: 15px;
            font-size: 0.95em;
        }

        .references li a {
            color: #00FFCC; /* Bright green for links */
            text-decoration: none;
        }

        .references li a:hover {
            text-decoration: underline;
            color: #33CCFF; /* Lighter blue on hover */
        }

        /* --- Section 5.4 & 5.5 Specific Styles --- */
        .framework-section h3 {
            font-size: 2.2em; /* Make these section headers larger */
            color: #00FFCC; /* Bright green for emphasis */
            text-shadow: 0 0 15px rgba(0, 255, 204, 0.7);
            border-bottom: 2px solid #00FFCC;
            padding-bottom: 10px;
            margin-top: 60px;
            letter-spacing: 1px;
            text-align: center;
        }

        .framework-dimension {
            background-color: rgba(0, 255, 204, 0.05); /* Subtle glowing background */
            border-left: 4px solid #00FFCC;
            padding: 25px;
            margin-bottom: 30px;
            border-radius: 5px;
            box-shadow: 0 0 10px rgba(0, 255, 204, 0.3);
            transition: transform 0.3s ease-in-out, box-shadow 0.3s ease-in-out; /* Subtle animation effect */
        }

        .framework-dimension:hover {
            transform: translateY(-5px); /* Lift effect on hover */
            box-shadow: 0 0 20px rgba(0, 255, 204, 0.6), 0 0 30px rgba(51, 204, 255, 0.3); /* Enhanced glow */
        }

        .framework-dimension h4 {
            color: #33CCFF; /* Dimension sub-headers */
            font-size: 1.8em;
            margin-bottom: 15px;
            border-bottom: 1px dashed #33CCFF;
            padding-bottom: 5px;
        }

        .framework-dimension ul {
            list-style-type: '‚ö° '; /* Custom lightning bolt bullet */
            margin-left: 10px;
            font-size: 1.1em; /* Slightly larger text for list items */
            color: #E0E0E0;
        }

        .framework-dimension ul li {
            margin-bottom: 8px;
        }

        .framework-dimension strong {
            color: #00FFFF;
            font-size: 1.1em; /* Emphasize key terms */
        }

        .implementation-path {
            background-color: rgba(0, 191, 255, 0.05); /* Blueish tint for this section */
            border-left: 4px solid #00BFFF;
            padding: 25px;
            margin-top: 40px;
            border-radius: 5px;
            box-shadow: 0 0 10px rgba(0, 191, 255, 0.3);
        }

        .implementation-path h4 {
            color: #00BFFF;
            font-size: 1.8em;
            margin-bottom: 15px;
            border-bottom: 1px dashed #00BFFF;
            padding-bottom: 5px;
        }

        .implementation-path ul {
            list-style-type: 'üöÄ '; /* Rocket emoji bullet */
            margin-left: 10px;
            font-size: 1.1em;
            color: #E0E0E0;
        }

        .implementation-path .prediction {
            font-size: 1.3em;
            color: #FFD700; /* Gold for prediction */
            text-align: center;
            margin-top: 30px;
            padding: 15px;
            border: 1px solid #FFD700;
            border-radius: 5px;
            background-color: rgba(255, 215, 0, 0.05);
            box-shadow: 0 0 15px rgba(255, 215, 0, 0.4);
            font-weight: bold;
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>üîç CLAUDIN18.2 Target: In-Depth Research Report</h1>

        <div class="section-header"><span>üìå</span>I. Target Origin and Basic Biological Mechanism</div>
        <h3>1.1 Discovery History of the Claudin18 Gene</h3>
        <p>The Claudin18 gene was first discovered in 1998 as an important member of the tight junction protein family. Through in-depth research into the structure and function of tight junction proteins, scientists identified two key splice variants of Claudin18: Claudin18.1 and Claudin18.2.</p>
        <p>The significance of this discovery lies in revealing the molecular basis of tissue-specific expression:</p>
        <ul>
            <li><strong>Claudin18.1</strong>: Primarily expressed in lung tissue, involved in tight junctions between alveolar epithelial cells.</li>
            <li><strong>Claudin18.2</strong>: Specifically expressed in differentiated epithelial cells of the gastric mucosa. This unique tissue distribution laid the foundation for subsequent targeted therapies.</li>
        </ul>
        <img src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41571-024-00874-2/MediaObjects/41571_2024_874_Fig2_HTML.png?as=webp" alt="Claudin18.1 and Claudin18.2 Expression">


        <h3>1.2 Mechanism of Claudin18.2's Gastric Epithelial Specific Expression</h3>
        <p>Claudin18.2, as a four-transmembrane protein, holds profound biological significance due to its specific expression in the gastric epithelium:</p>
        <h4>Molecular Structural Features:</h4>
        <img src="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41571-024-00874-2/MediaObjects/41571_2024_874_Fig1_HTML.png?as=webp" alt="Claudin 18.2 structure, function and expression patterns.">
        <ul>
            <li>Belongs to the tight junction protein family, containing four transmembrane domains.</li>
            <li>Its primary function is to maintain cell barrier integrity and cell polarity.</li>
            <li>In normal gastric mucosa, it is exclusively expressed within the tight junctions of differentiated epithelial cells.</li>
        </ul>
        <h4>Uniqueness of Expression Pattern:</h4>
        <ul>
            <li>Not expressed in gastric stem cell regions; found only in differentiated gastric epithelial cells.</li>
            <li>This differentiation-dependent expression pattern makes it an ideal tumor biomarker.</li>
            <li>Under normal conditions, it is tightly sealed within the intercellular tight junction complex.</li>
        </ul>

        <h3>1.3 Epitope Exposure Mechanism in Cancer Cells</h3>
        <p>The transformation of Claudin18.2 from "hidden" to "exposed" is pivotal to its success as a therapeutic target:</p>
        <h4>"Hidden" in Normal State:</h4>
        <ul>
            <li>Located at the very top of the intercellular space.</li>
            <li>Binds with Claudin18.2 molecules on adjacent cell surfaces to form tight junction complexes.</li>
            <li>Buried within the supramolecular complex of tight junctions, making it inaccessible to antibodies.</li>
        </ul>
        <h4>"Exposed" in Tumor State:</h4>
        <ul>
            <li>Malignant tumor development leads to the disruption of tight junction structures.</li>
            <li>The Claudin18.2 epitope on the tumor cell surface becomes fully exposed.</li>
            <li>It thereby becomes a target that antibody drugs can specifically recognize and bind to.</li>
        </ul>

        <h3>1.4 Milestone Discovery of Tumor-Selective Expression</h3>
        <h4>Groundbreaking Research:</h4>
        <ul>
            <li>Research by Sentani Kazuhiro et al. in 2008 first described the stable high expression of Claudin18.2 in gastric cancer.</li>
            <li>In the same year, crucial research by U. ≈ûahin et al. highlighted Claudin18.2's highly selective expression across various cancer types.</li>
        </ul>
        <h4>Discovery of Broad Expression Profile:</h4>
        <ul>
            <li><strong>Gastric Cancer</strong>: The predominant cancer type expressing this target.</li>
            <li><strong>Pancreatic Cancer</strong>: Exhibits significant abnormal activation.</li>
            <li><strong>Esophageal Cancer, Ovarian Cancer, Lung Cancer</strong>: Shows aberrant activation in various solid tumors.</li>
            <li>This broad expression characteristic substantially expands its therapeutic application prospects.</li>
        </ul>

        <hr>

        <div class="section-header"><span>üìå</span>II. Research & Development Pathway and Target Value Assessment</div>
        <h3>2.1 Transformation from Structural Protein to Therapeutic Target</h3>
        <h4>Key Milestones in Target Development:</h4>
        <ol>
            <li>Basic Discovery Phase: Initial functional studies as a tight junction protein.</li>
            <li>Aberrant Expression Discovery: Identification of its abnormal expression patterns in gastric cancer and other tumors.</li>
            <li>Druggability Assessment: Validation of epitope exposure and antibody accessibility.</li>
            <li>Broad Potential Confirmation: Verification of its expression across various cancer types.</li>
            <li>Clinical Translation: Successful transition from laboratory research to clinical trials.</li>
        </ol>
        <p>This translational process illustrates the complete journey of modern precision medicine from foundational research to clinical application.</p>

        <h3>2.2 Multi-Cancer Expression Profile and Clinical Significance</h3>
        <h4>Detailed Expression Data:</h4>
        <table>
            <thead>
                <tr>
                    <th>Cancer Type</th>
                    <th>Positive Expression Rate</th>
                    <th>Expression Intensity</th>
                    <th>Clinical Significance</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Gastric Cancer</td>
                    <td>60%-80%</td>
                    <td>High-Very High</td>
                    <td>Primary indication, greatest patient benefit</td>
                </tr>
                <tr>
                    <td>Pancreatic Cancer</td>
                    <td>50%-60%</td>
                    <td>Medium-High</td>
                    <td>Important expanded indication</td>
                </tr>
                <tr>
                    <td>Esophageal Cancer</td>
                    <td>40%-50%</td>
                    <td>Medium</td>
                    <td>Potential therapeutic opportunity</td>
                </tr>
                <tr>
                    <td>Ovarian Cancer</td>
                    <td>30%-40%</td>
                    <td>Medium</td>
                    <td>Emerging therapeutic area</td>
                </tr>
                <tr>
                    <td>Lung Cancer</td>
                    <td>20%-30%</td>
                    <td>Low-Medium</td>
                    <td>Specific subtype benefit</td>
                </tr>
            </tbody>
        </table>
        <h4>Relationship between Expression Intensity and Prognosis:</h4>
        <ul>
            <li>High expression often correlates closely with tumor invasiveness and metastatic potential.</li>
            <li>Expression levels can serve as a vital biomarker for prognostic assessment and treatment selection.</li>
        </ul>

        <h3>2.3 Preclinical Model Validation Results</h3>
        <h4>Mouse Model Research Achievements:</h4>
        <ul>
            <li><strong>Organoid Models</strong>: Patient-derived organoid models have demonstrated excellent anti-tumor activity, offering a more physiologically relevant and high-throughput platform for drug screening and personalized medicine.</li>
            <li><strong>Syngeneic Models</strong>: Zolbetuximab significantly inhibited tumor growth in gastric cancer mouse models.</li>
            <li><strong>Extended Survival</strong>: Multiple studies show significantly prolonged survival, with some achieving complete tumor remission.</li>
            <li><strong>Safety Assessment</strong>: Exhibited a favorable tolerability and safety profile.</li>
        </ul>
        <h4>Mechanism Validation Studies:</h4>
        <ul>
            <li>Antibody-dependent cellular cytotoxicity (ADCC)</li>
            <li>Complement-dependent cytotoxicity (CDC)</li>
            <li>Direct cell signaling interference</li>
        </ul>

        <h3>2.4 Comparative Advantage Analysis with Classic Targets</h3>
        <h4>Core Competitive Advantages:</h4>
        <table>
            <thead>
                <tr>
                    <th>Comparison Dimension</th>
                    <th>Claudin18.2</th>
                    <th>HER2</th>
                    <th>EGFR</th>
                    <th>EpCAM</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Tissue Specificity</td>
                    <td>Extremely High (Gastric Specific)</td>
                    <td>Medium</td>
                    <td>Low</td>
                    <td>Low</td>
                </tr>
                <tr>
                    <td>Normal Tissue Expression</td>
                    <td>Extremely Low</td>
                    <td>Medium</td>
                    <td>High</td>
                    <td>Medium</td>
                </tr>
                <tr>
                    <td>Tumor Selectivity</td>
                    <td>Extremely High</td>
                    <td>High</td>
                    <td>Medium</td>
                    <td>Medium</td>
                </tr>
                <tr>
                    <td>Patient Coverage</td>
                    <td>60%-80%</td>
                    <td>15%-20%</td>
                    <td>60%-70%</td>
                    <td>Broad</td>
                </tr>
                <tr>
                    <td>Resistance Risk</td>
                    <td>Low</td>
                    <td>High</td>
                    <td>Extremely High</td>
                    <td>Medium</td>
                </tr>
                <tr>
                    <td>Safety</td>
                    <td>Excellent</td>
                    <td>Good</td>
                    <td>General</td>
                    <td>Good</td>
                </tr>
            </tbody>
        </table>
        <h4>Claudin18.2's Target Superiority:</h4>
        <ul>
            <li>Unparalleled tissue specificity: Expressed exclusively in specific tumors like gastric cancer.</li>
            <li>Broad patient benefit potential: Covers a wide range of solid tumor types.</li>
            <li>Low resistance risk: Benefits from a novel mechanism of action.</li>
            <li>Excellent safety profile: Exhibits minimal off-target effects.</li>
        </ul>

        <hr>

        <div class="section-header"><span>üìå</span>III. Drug Development and Clinical Breakthroughs</div>
        <img src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41571-024-00874-2/MediaObjects/41571_2024_874_Fig4_HTML.png?as=webp" alt="Drug Development and Clinical Breakthroughs Illustration">
        <p>Mechanisms of action of the various classes of developmental claudin 18.2-targeted therapies.</p>


        <h3>3.1 Zolbetuximab Development Journey and Milestones</h3>
        <h4>Company Development Trajectory:</h4>
        <ul>
            <li><strong>Ganymed Pharmaceuticals</strong>: A German biotechnology company, the original developer of Zolbetuximab.</li>
            <li><strong>2016</strong>: Astellas acquired Ganymed for a total value of ‚Ç¨1.28B.</li>
            <li><strong>BioNTech</strong>: Subsequently participated in development through technology transfer.</li>
        </ul>
        <h4>Clinical Development Timeline:</h4>
        <ul>
            <li><strong>2009</strong>: First entered clinical trials.</li>
            <li><strong>2016</strong>: Phase II trials showed promising signals.</li>
            <li><strong>2020-2023</strong>: Key Phase III trials (GLOW, SPOTLIGHT).</li>
            <li><strong>March 2024</strong>: First approved for market in Japan.</li>
            <li><strong>October 2024</strong>: Officially approved by the FDA.</li>
        </ul>

        <h3>3.2 Global Regulatory Approval Status</h3>
        <h4>Detailed Approval Information:</h4>
        <table>
            <thead>
                <tr>
                    <th>Region/Country</th>
                    <th>Approval Date</th>
                    <th>Indication</th>
                    <th>Brand Name</th>
                    <th>Notes</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Japan</td>
                    <td>March 2024</td>
                    <td>CLDN18.2+, HER2- Gastric Cancer/GEJ Adenocarcinoma</td>
                    <td>Vyloy</td>
                    <td>First global approval</td>
                </tr>
                <tr>
                    <td>United States</td>
                    <td>October 2024</td>
                    <td>Same as above</td>
                    <td>Vyloy</td>
                    <td>FDA accelerated approval</td>
                </tr>
                <tr>
                    <td>European Union</td>
                    <td>Under review</td>
                    <td>Same as above</td>
                    <td>Pending</td>
                    <td>Expected late 2024</td>
                </tr>
                <tr>
                    <td>China</td>
                    <td>January 2025</td>
                    <td>Same as above</td>
                    <td>Zolbetuximab</td>
                    <td>First CLDN18.2 mAb in China</td>
                </tr>
            </tbody>
        </table>
        <p><strong>Specific Indication Description</strong>: "In combination with fluoropyrimidine and platinum-containing chemotherapy, for the treatment of patients with Claudin18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma."</p>

        <h3>3.3 Rich Pipeline of Investigational Drugs</h3>
        <h4>CAR-T Cell Therapies:</h4>
        <ul>
            <li><strong>CT041</strong>: Developed by Carsgen Therapeutics, already in clinical trials.</li>
            <li><strong>AB011</strong>: Another important CAR-T candidate.</li>
            <li>These therapies represent the cutting edge of cellular immunotherapy.</li>
        </ul>
        <h4>Antibody-Drug Conjugates (ADCs):</h4>
        <ul>
            <li><strong>CMG901</strong>: Has entered Phase III clinical trials.</li>
            <li><strong>SHR-A1904</strong>: Developed by Hengrui Medicine.</li>
            <li><strong>LM302</strong>: Another ADC candidate that has entered Phase III.</li>
        </ul>
        <h4>Bispecific Antibodies:</h4>
        <ul>
            <li><strong>TST001</strong>: An innovative dual-target design.</li>
            <li><strong>M108</strong>: Possesses a unique mechanism of action.</li>
            <li><strong>ASKB589</strong>: China's first CLDN18.2 monoclonal antibody to enter Phase III.</li>
        </ul>

        <h3>3.4 Combination Therapy Strategies</h3>
        <h4>Validated Combination Regimens:</h4>
        <ul>
            <li><strong>Chemotherapy Combination</strong>: Synergistic effects with fluoropyrimidine and platinum-based chemotherapy.</li>
            <li><strong>Immunotherapy Combination</strong>: Ongoing research on combination with PD-1/PD-L1 inhibitors.</li>
            <li><strong>Multi-target Combination</strong>: Strategies for combining with other targeted drugs.</li>
        </ul>
        <h4>Future Development Directions:</h4>
        <ul>
            <li>Exploration of triple or even quadruple therapy regimens.</li>
            <li>Application in neoadjuvant and adjuvant therapy settings.</li>
            <li>Development of novel maintenance therapy strategies.</li>
        </ul>

        <hr>

        <div class="section-header"><span>üìå</span>IV. Market Data and In-Depth Commercial Potential Analysis</div>
        <h3>4.1 Zolbetuximab Market Expectations and Valuation</h3>
        <h4>Authoritative Agency Forecasts:</h4>
        <ul>
            <li>EvaluatePharma predicts: Peak sales are expected to reach <strong>$1.0-1.5 billion</strong>.</li>
            <li>GlobalData analysis: Full commercialization anticipated between 2025-2030.</li>
            <li>Market entry timing: Expected to be fully launched in major markets by 2025.</li>
        </ul>
        <h4>Sales Growth Forecast Model:</h4>
        <ul>
            <li><strong>2025</strong>: $200-300M (initial market penetration).</li>
            <li><strong>2027</strong>: $800M-1.2B (rapid growth phase).</li>
            <li><strong>2030</strong>: $1.5-2.0B (peak sales in maturity phase).</li>
        </ul>

        <h3>4.2 Carsgen's CLDN18.2 CAR-T Valuation Analysis</h3>
        <h4>Funding and Valuation Status:</h4>
        <ul>
            <li>Total funding raised: Exceeding <strong>$500M</strong>.</li>
            <li>Valuation level: Based on the high growth potential of the CAR-T technology platform.</li>
            <li>IPO plan: Expected to list on NASDAQ or HKEX in 2025.</li>
            <li>Technological value: Reflects breakthrough progress of CAR-T cell therapy in solid tumors.</li>
        </ul>
        <h4>Market Positioning Advantages:</h4>
        <ul>
            <li>Pioneer in solid tumor CAR-T therapy.</li>
            <li>Early mover in targeting CLDN18.2.</li>
            <li>Strong advantages in technological barriers and patent protection.</li>
        </ul>

        <h3>4.3 Commercialization Progress in China and Asian Markets</h3>
        <h4>Key Players in the Chinese Market:</h4>
        <table>
            <thead>
                <tr>
                    <th>Company</th>
                    <th>Product</th>
                    <th>Development Phase</th>
                    <th>Key Advantage</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Fosun Pharma</td>
                    <td>HLX26</td>
                    <td>Phase III</td>
                    <td>ADC Technology Platform</td>
                </tr>
                <tr>
                    <td>Innovent Biologics</td>
                    <td>IBI354</td>
                    <td>Phase II</td>
                    <td>Monoclonal Antibody + ADC dual pipeline</td>
                </tr>
                <tr>
                    <td>Carsgen Therapeutics</td>
                    <td>CT041</td>
                    <td>Phase I/II</td>
                    <td>CAR-T Cell Therapy</td>
                </tr>
                <tr>
                    <td>Hengrui Medicine</td>
                    <td>SHR-A1904</td>
                    <td>Phase III</td>
                    <td>Major ADC Product</td>
                </tr>
            </tbody>
        </table>
        <h4>Characteristics of Asian Markets:</h4>
        <ul>
            <li><strong>High incidence of gastric cancer</strong>: China, Japan, and South Korea have some of the highest gastric cancer incidence rates globally.</li>
            <li><strong>Huge patient base</strong>: Estimated over 500,000 potential patients.</li>
            <li><strong>Increasing affordability</strong>: Progress in medical insurance coverage and commercial insurance development.</li>
            <li><strong>Optimized regulatory environment</strong>: Accelerated approval processes and supportive innovative drug policies.</li>
        </ul>

        <h3>4.4 Investment Transactions and Partnership Model Analysis</h3>
        <h4>Major Transaction Cases:</h4>
        <ul>
            <li>Astellas' acquisition of Ganymed: ‚Ç¨1.28B, a record-setting biotech company acquisition.</li>
            <li>BioNTech technology licensing: Multi-faceted technology transfer and collaboration.</li>
            <li>Chinese enterprise licensing-in: Several companies have acquired technology through licensing agreements.</li>
        </ul>
        <h4>Innovation in Partnership Models:</h4>
        <ul>
            <li>Risk-sharing collaborations: Jointly bearing development risks and costs.</li>
            <li>Regional exclusive licenses: Exclusive development rights delineated by geographic region.</li>
            <li>Technology platform partnerships: Deep collaborations based on shared technological platforms.</li>
        </ul>

        <hr>

        <div class="section-header"><span>üìå</span>V. Target Uniqueness and Replicability: An In-depth Analysis (Core Value Analysis)</div>
        <h3>5.1 Claudin18.2 vs Claudin18.1: Precise Splice Variant Selection</h3>
        <h4>Molecular Level Difference Analysis:</h4>
        <table>
            <thead>
                <tr>
                    <th>Comparison Dimension</th>
                    <th>Claudin18.2</th>
                    <th>Claudin18.1</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Tissue Distribution</td>
                    <td>Gastric epithelial specific</td>
                    <td>Lung expression</td>
                </tr>
                <tr>
                    <td>Tumor Expression</td>
                    <td>Highly selective</td>
                    <td>Lower selectivity</td>
                </tr>
                <tr>
                    <td>Antibody Specificity</td>
                    <td>Extremely High</td>
                    <td>Medium</td>
                </tr>
                <tr>
                    <td>Safety Window</td>
                    <td>Very Wide</td>
                    <td>Relatively Narrow</td>
                </tr>
                <tr>
                    <td>Drug Development Difficulty</td>
                    <td>Low</td>
                    <td>High</td>
                </tr>
            </tbody>
        </table>
        <h4>Molecular Basis of Antibody Selectivity:</h4>
        <ul>
            <li>Epitope structural differences: Amino acid sequence variations exist in key epitope regions between the two subtypes.</li>
            <li>Conformational stability: Claudin18.2 demonstrates a more stable conformation in the tumor microenvironment.</li>
            <li>Immunogenicity: Claudin18.2 possesses stronger immunogenicity, facilitating the generation of highly specific antibodies.</li>
        </ul>

        <h3>5.2 Structural Exon Stability Analysis</h3>
        <h4>Molecular Structural Features:</h4>
        <ul>
            <li>Exon composition: Consists of two extracellular loop structures (ECL1 and ECL2).</li>
            <li>Structural stability: Maintains stability under both physiological and pathological conditions.</li>
            <li>Antibody binding site: Primarily located within the first extracellular loop region.</li>
        </ul>
        <h4>Epitope Exposure Mechanism in the Tumor Microenvironment:</h4>
        <ol>
            <li>Tight junction disruption: Intercellular connections are lost during tumor growth.</li>
            <li>Epitope exposure: The previously hidden antibody binding sites become fully exposed.</li>
            <li>Stable binding: Antibodies form stable immune complexes with the target.</li>
            <li>Therapeutic effect: Exerts anti-tumor effects through mechanisms like ADCC and CDC.</li>
        </ol>

        <h3>5.3 Systematic Analysis of Similar Targets</h3>
        <h4>Other Junction/Adhesion Molecules with Similar Characteristics:</h4>
        <table>
            <thead>
                <tr>
                    <th>Protein Name</th>
                    <th>Similar Characteristics</th>
                    <th>Limitations</th>
                    <th>Development Prospects</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>E-cadherin</td>
                    <td>Cell adhesion, abnormal in tumors</td>
                    <td>Widespread normal tissue expression</td>
                    <td>Medium</td>
                </tr>
                <tr>
                    <td>Occludin</td>
                    <td>Tight junction protein</td>
                    <td>Insufficient tissue specificity</td>
                    <td>Lower</td>
                </tr>
                <tr>
                    <td>Claudin1</td>
                    <td>Tight junction protein</td>
                    <td>Multi-organ expression</td>
                    <td>Medium</td>
                </tr>
                <tr>
                    <td>JAM-A</td>
                    <td>Cell adhesion molecule</td>
                    <td>Overly broad expression profile</td>
                    <td>Lower</td>
                </tr>
            </tbody>
        </table>
        <h4>Claudin18.2's Unique Advantages:</h4>
        <ul>
            <li>Unmatched tissue specificity.</li>
            <li>Ideal tumor-to-normal tissue expression ratio.</li>
            <li>Excellent antibody accessibility.</li>
            <li>Robust clinical validation data.</li>
        </ul>

        <div class="framework-section">
            <h3>5.4 "Next Claudin18.2" Discovery Framework Construction</h3>
            <p style="font-size: 1.3em; color: #00FFFF; text-align: center; margin-bottom: 30px; text-shadow: 0 0 10px rgba(0, 255, 255, 0.5);">
                Establishing a Replicable Systematic Screening Strategy to Uncover Novel Tumor Targets
            </p>

            <div class="framework-dimension">
                <h4>üéØ Dimension 1: Subcellular Localization + Cancer-Specific Expression</h4>
                <ul>
                    <li><strong>Screening Criteria</strong>:
                        <ul>
                            <li><strong>Restricted Normal Tissue Expression</strong>: Exclusively expressed in specific cell types or tissues, akin to Claudin18.2 in gastric epithelium.</li>
                            <li><strong>Significant Ectopic/Upregulated Expression in Cancer Cells</strong>: Dramatically increased or aberrantly exposed in tumors, such as Claudin18.2 "emerging" due to disrupted tight junctions.</li>
                            <li><strong>Cell Surface or Junctional Localization</strong>: Prioritize proteins situated on the cell membrane or within tight/adherens junctions to ensure antibody accessibility.</li>
                        </ul>
                    </li>
                    <li><strong>Candidate Target Types</strong>:
                        <ul>
                            <li>Other Claudin family splice variants (e.g., Claudin18.1, Claudin1.2), investigating their expression patterns in different tissues.</li>
                            <li>Specific cadherin subtypes (e.g., E-cadherin, N-cadherin), examining their expression and function across various tissues.</li>
                            <li>Tissue-specific integrin subunits (e.g., Œ±vŒ≤6, Œ±vŒ≤3), studying their expression and function in particular tissues.</li>
                        </ul>
                    </li>
                </ul>
            </div>

            <div class="framework-dimension">
                <h4>üî¨ Dimension 2: Splice Variant Specificity Mining</h4>
                <ul>
                    <li><strong>Research Directions</strong>:
                        <ul>
                            <li>Systematic analysis of <strong>aberrant splicing events</strong> in tumors: Identify tumor-specific transcripts through RNA-seq and single-cell sequencing.</li>
                            <li>Identification of <strong>tumor-specific splice variants</strong>: Screen for splice variants uniquely expressed in tumor tissues, mirroring Claudin18.2's specific expression in gastric cancer.</li>
                            <li>Validation of their <strong>function and expression patterns</strong>: Confirm the function and expression patterns of splice variants through proteomic analysis and immunohistochemistry.</li>
                        </ul>
                    </li>
                    <li><strong>Key Technological Approaches</strong>:
                        <ul>
                            <li><strong>Long-read RNA-seq</strong> (Oxford Nanopore, PacBio): Utilize these technologies to capture full-length transcripts and identify complex splicing events and isoforms.</li>
                            <li><strong>Single-cell Multi-omics</strong>: Employ single-cell RNA-seq and single-cell proteomics to analyze splicing patterns and expression differences across various cellular states.</li>
                            <li><strong>Ribosome Profiling</strong>: Integrate with ribosome profiling data to investigate the translation efficiency and function of splice variants.</li>
                            <li><strong>AlphaFold2 Structure Prediction</strong>: Use AlphaFold2 to predict protein structures, analyzing conformational changes and functional impacts of splice variants.</li>
                        </ul>
                    </li>
                </ul>
            </div>

            <div class="framework-dimension">
                <h4>üß¨ Dimension 3: Structural Exon Stability Assessment</h4>
                <ul>
                    <li><strong>Assessment Metrics</strong>:
                        <ul>
                            <li><strong>Protein Structure Prediction and Stability Analysis</strong>: Utilize AlphaFold2 to predict protein structures and evaluate the stability and external structural domains of splice variants.</li>
                            <li><strong>Antibody Binding Site Accessibility</strong>: Determine, through structural biology research, whether the external domains of splice variants are easily recognized by antibodies.</li>
                            <li><strong>Stability in the Tumor Microenvironment</strong>: Evaluate the expression stability of splice variants in tumor tissue, such as Claudin18.2's specific expression in gastric cancer.</li>
                        </ul>
                    </li>
                    <li><strong>Key Validation Methods</strong>:
                        <ul>
                            <li><strong>Antibody Screening and Specificity Validation</strong>: Confirm the specificity of splice variants through antibody screening and functional validation.</li>
                            <li><strong>In Vitro and In Vivo Functional Validation</strong>: Validate the anti-tumor activity of splice variants through in vitro experiments and animal models.</li>
                        </ul>
                    </li>
                </ul>
            </div>

            <div class="framework-dimension">
                <h4>üåê Dimension 4: In-depth Tissue Specificity Mining</h4>
                <ul>
                    <li><strong>Key Organ Systems</strong>:
                        <ul>
                            <li><strong>Digestive System</strong>: Such as liver, pancreas, and colon-specific markers, akin to Claudin18.2's specific expression in gastric cancer.</li>
                            <li><strong>Urogenital System</strong>: Such as prostate, ovary, and kidney-specific molecules, similar to Claudin18.2's specific expression in gastric cancer.</li>
                            <li><strong>Nervous System</strong>: Such as blood-brain barrier-related molecules, as observed with Claudin18.2's specific expression in gastric cancer.</li>
                        </ul>
                    </li>
                    <li><strong>Screening Methods</strong>:
                        <ul>
                            <li><strong>Tissue-Specific Transcriptome Database Mining</strong>: Utilize databases like TCGA and COSMIC to screen for tissue-specific genes and splice variants.</li>
                            <li><strong>Single-cell Atlas Analysis</strong>: Analyze cell states and gene expression in different tissues using single-cell sequencing technology.</li>
                            <li><strong>Comparative Proteomics Research</strong>: Identify tissue-specific molecules by comparing proteomic data from various tissues.</li>
                        </ul>
                    </li>
                </ul>
            </div>
        </div>

        <div class="framework-section">
            <h3>5.5 Implementation Path of the Discovery Framework: A Three-Phase Strategy</h3>
            <div class="implementation-path">
                <h4><span style="color:#00FFCC;">üöÄ</span> Phase One: Bioinformatics Big Data Screening</h4>
                <ul>
                    <li><strong>Massive Databases</strong>: Deeply mine large-scale transcriptome/proteome databases such as TCGA and GTEx.</li>
                    <li><strong>Precise Filtering</strong>: Systematically screen for <strong>tissue-specific</strong> gene expression, prioritizing membrane proteins and cell surface molecules.</li>
                </ul>
            </div>
            <div class="implementation-path">
                <h4><span style="color:#33CCFF;">üß™</span> Phase Two: Multi-Dimensional Experimental Validation</h4>
                <ul>
                    <li><strong>Accurate Expression Profile Validation</strong>: Confirm the expression patterns of candidate targets in both normal and tumor tissues.</li>
                    <li><strong>High-Specificity Antibody Development and Testing</strong>: Ensure antibodies can precisely recognize the target.</li>
                    <li><strong>Cell and Animal Model Functional Validation</strong>: Conduct preliminary assessments of the anti-tumor potential of targeted interventions.</li>
                </ul>
            </div>
            <div class="implementation-path">
                <h4><span style="color:#FFD700;">üìà</span> Phase Three: Accelerated Clinical Translation</h4>
                <ul>
                    <li><strong>Rigorous Preclinical Evaluation</strong>: Comprehensively assess pharmacology, toxicology, and safety.</li>
                    <li><strong>Companion Diagnostic Development</strong>: Simultaneously develop biomarkers for patient screening.</li>
                    <li><strong>Optimized Clinical Trial Design</strong>: Efficiently advance clinical validation from Phase I to Phase III.</li>
                </ul>
            </div>
            <p class="prediction">
                <strong>üí° Success Case Prediction:</strong> Based on this systematic framework, we anticipate the discovery and successful development of <strong>2-3</strong> excellent tumor targets with characteristics comparable to Claudin18.2 within the next <strong>5-10 years</strong>, bringing new breakthroughs to precision medicine and cancer treatment!
            </p>
        </div>

        <hr>

        <h2>Conclusion and Outlook</h2>
        <p>Claudin18.2, as a groundbreaking therapeutic target in oncology, has proven successful not only in its excellent clinical performance and immense commercial value but also, more importantly, by providing a replicable success model for future target discovery and drug development. Through systematic research and analysis, we can establish effective frameworks to identify the "next Claudin18.2," opening up more possibilities for precision cancer therapy.</p>

        <div class="references">
            <h4>References</h4>
            <ul>
                <li>Nakayama, I., Qi, C., Chen, Y. et al. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol 21, 354‚Äì369 (2024). <a href="https://doi.org/10.1038/s41571-024-00874-2" target="_blank"></li>
                <li>Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189‚Äì1198 (2022).</li>
                <li>A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors.</li>
                <li>Sahin, U. et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14, 7624‚Äì7634 (2008).</li>
                <li>Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K. & Tsukita, S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 141, 1539‚Äì1550 (1998).</li>
            </ul>
        </div>
    </div>
</body>
</html>
